Specialty chemicals group Elementis plc (LSE:ELM) has edged its 2026 adjusted operating profit guidance to $133–135 million, slightly above its previous guidance, after nine-month revenue rose 7% on an organic constant currency basis to $479 million.
What was announced
On 28 October 2026, Elementis plc, which describes itself as "the pure-play specialty chemicals business", published a trading update for the third quarter, the three months to 30 September 2026. The main point was a modest upgrade to the company's full-year profit guidance.
Elementis said it now expects adjusted operating profit for 2026 of $133–135 million. The company described this as "slightly above its previous guidance" and "in line with the latest market expectations", reflecting "continued trading progress despite mixed market conditions".
The update did not give standalone third-quarter revenue or profit figures, margin data, net debt or any dividend information.
The numbers
Revenue for the nine months to 30 September 2026 was $479 million, up 7% on an organic constant currency basis. The company said this growth was led by Personal Care, helped by continued momentum in Asia and an improved performance in the Americas.
Elementis also published a company-compiled analyst consensus. At the half-year stage, consensus for 2026 adjusted operating profit was $132.5 million, within a range of $129.4–136.5 million. The current consensus is $134.7 million, within a range of $132.0–140.1 million. On the disclosed figures, the midpoint of the new guidance range, $134 million, is about 1% above the half-year consensus figure and slightly below the current consensus figure, which sits inside the guided range.
The company cautioned that it expects fourth-quarter revenue to be lower than the third quarter, in line with typical seasonality. It added that the third quarter "benefitted from fulfilling earlier than anticipated customer orders", meaning some revenue was pulled forward. Even so, Elementis (LSE:ELM) said it "remains on track to deliver further progress in the second half of the year".
Segment commentary
In Personal Care, revenue growth accelerated in all regions, against what the company called a weaker prior-year comparator. Performance in the Americas improved further, and September benefited from favourable timing of customer orders.
In Coatings, the Energy business performed well. Elementis attributed this to operational improvements at its St. Louis plant in the US and to solid demand. Coatings performance in the Americas improved after a weak first half, and strength in Asia offset weaker trading in Europe, the Middle East and Africa. The company expects Coatings growth to moderate in the fourth quarter because of a high prior-year comparator in Asia.
Chief executive Luc van Ravenstein said: "Our 'Elevate Elementis' strategy is progressing well." He linked the growth to "Elementis' high-quality capabilities in specialty chemicals and a simpler, leaner model that puts customers first".
Background and what to watch next
Elevate Elementis, the strategy launched in 2025, sets medium-term targets of mid-single-digit revenue growth through the cycle, an adjusted operating profit margin of 23% or more, three-year operating cash conversion above 90%, and a return on capital employed, excluding goodwill, above 30%. The update did not say how far the business is from the margin, cash conversion or return targets.
The company said it will hold an Innovation Day the following week, where management plans to discuss the innovation behind its growth. Investors may look to that event for more detail on the product pipeline and on progress towards the medium-term targets.
The next scheduled marker is the full-year 2026 result, which will show whether adjusted operating profit lands within the $133–135 million range the company has guided. Given the company's own warning about fourth-quarter seasonality and pulled-forward orders, the split between the third and fourth quarters will also be worth watching. Chief financial officer Kath Kearney-Croft is the other named contact for investor enquiries.




_11_18_2026_14_55_02_703826.jpg)

Please wait processing your request...